Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body™

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2243-2252

  Coronella, Julia ^a   Li, Lingna ^a   Johnson, Kimberly ^a   Pirie Shepherd, Steven ^a   Roxas, Giovanni ^a   Levin, Nancy ^a  

^a CovX Research LLC ^*  (United States)

Author keywords

Antiangiogenic; Antibody; Endothelial cell; Peptide; Selectivity; Thrombospondin 1

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BROXURIDINE; COVX BODY; CVX 1212; CVX 22; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DENSITY; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; DRUG SELECTIVITY; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MELANOMA C32; MITOSIS RATE; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN G; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR MIMICRY; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; THROMBOSPONDIN 1; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67650908912     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Maeda K, Nishiguchi Y, Kang SM, Yashiro M, Onoda N, Sawada T et al: Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 8(4): 763-766, 2001. (Pubitemid 33758118)
2. Yamaguchi M, Sugio K, Ondo K, Yano T and Sugimachi K: Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36(2): 143-150, 2002. (Pubitemid 34296556)
3. Tobita K, Kijima H, Dowaki S, Oida Y, Kashiwagi H, Ishii M et al: Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 21(6): 1189-1195, 2002.
4. Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H et al: Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis. Clin Cancer Res 7(9): 2826-2831, 2001. (Pubitemid 32911392)
5. Yao L, Zhao YL, Itoh S, Wada S, Yue L and Furuta I: Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival. Oral Oncol 36(6): 539-544, 2000. (Pubitemid 30742239)
6. Maeda K, Nishiguchi Y, Yashiro M, Yamada S, Onoda N, Sawada T et al: Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5(4): 373-378, 2000.
7. Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H et al: Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res 21(4B): 2983-2987, 2001. (Pubitemid 33051163)
8. Straume O and Akslen LA: Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 93(8): 933-938, 2005. (Pubitemid 41487020)
9. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J et al: Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64(5): 1570-1574, 2004. (Pubitemid 38428672)
10. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J et al: Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55(2): 332-338, 1099. (Pubitemid 29076031)
11. Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL and Silverstein RL: Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 107(1): 45-52, 2001. (Pubitemid 32047413)
12. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA and Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138(3): 707-717, 1997.
13. Young GD and Murphy-Ullrich JE: The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 279(46): 47633-47642, 2004. (Pubitemid 39540909)
14. Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J et al: Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 279(40): 41734-41743, 2004. (Pubitemid 39313619)
15. Yu H, Tyrrell D, Cashel J, Guo NH, Vogel T, Sipes JM et al: Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1. Arch Biochem Biophys 374(1): 13-23, 2000. (Pubitemid 30084403)
16. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J et al: Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 11(18): 6678-6685, 2005. (Pubitemid 41339009)
17. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE and Zetter BR: Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168(4): 643-653, 2005. (Pubitemid 40271029)
18. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM et al: Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48(8): 2838-2846, 2005. (Pubitemid 40548098)
19. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L et al: Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. Embo J 22(16): 4091-4102, 2003.
20. Yee KO, Streit M, Hawighorst T, Detmar M and Lawler J: Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165(2): 541-552, 2004. (Pubitemid 38971384)
21. Zhang X, Galardi E, Duquette M, Delic M, Lawler J and Parangi S: Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11(6): 2337-2344, 2005. (Pubitemid 40490195)
22. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J et al: Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98(5): 682-689, 2002. (Pubitemid 34225618)
23. Allegrini G, Goulette FA, Darnowski JW and Calabresi P: Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 53(3): 261-266, 2004. (Pubitemid 38293725)
24. Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S et al: In vivo up-regulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 12(6): 649-658, 2005.
25. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T et al: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6(2): 471-483, 2007. (Pubitemid 46332449)
26. Huang H, Do J, Rizzo J, Lai J-Y, Tryder N, Tumelty D et al: Enhancing thrombospondin-1 (TSP-1) mimetic antiangiogenic function using CovX-Body technology. AACR 97th Annual meeting, 2006; Washington, DC, 2006.
27. Li L, Leedom T, Johnson K, Johnson D, Huang H, Do J et al: Thrombospondin-1 (TSP-1) mimetic CovX-Body (CVX-22) reduces viable tumor mass in mouse models of cancer. AACR 97th Annual Meeting, 2006; Washington DC, 2006.
28. Doppalapudi VR, Tryder N, Li L, Aja T, Griffith D, Liao FF et al: Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodiestrade mark. Bioorg Med Chem Lett. 2006 Oct 7.
29. Hardwick JS, Yang Y, Zhang C, Shi B, McFall R, Koury EJ et al: Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiting. Mol Cancer Ther 4(3): 413-425, 2005.
30. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9): 3514-3522, 2005.
31. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA et al: Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22 Pt 1): 6689-6695, 2007. (Pubitemid 350206805)
32. Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ et al: A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17(8): 1320-1327, 2006. (Pubitemid 44288225)
33. Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R et al: Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 42(4): 467-472, 2006. (Pubitemid 43227924)
34. Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ et al: Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23(22): 5188-5197, 2005. (Pubitemid 46224028)
35. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R et al: Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7(11): 3366-3374, 2001. (Pubitemid 33069967)
36. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8): 1045-1047, 2000. (Pubitemid 30217688)